louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02355405: Diagnostic Values of Lung Ultrasound for Perioperative Atelectasis
Official title: Diagnostic Performance of Lung Ultrasound for Perioperative Atelectasis in Adult Patients Undergoing General Anesthesia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Postoperative Pulmonary Atelectasis
Keywords: lung ultrasound
atelectasis
thoracic computed Tomography
Lead sponsor: The Third Xiangya Hospital of Central South University
Sponsor class: OTHER
Collaborators: name: Xiangya Hospital of Central South University
First posted: 2015-02-04
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing selective neurosurgical operation in Xiangya Hospital or The Third Xiangya Hospital of Central South University

Brief summary: Lung ultrasound offers a novel, reliable and radiation-free tool for diagnosing perioperative atelectasis and evaluating its severity in adult patients undergoing general anesthesia in the operating room.

Detailed description: Atelectases occur in up to 90% of patients undergoing general anesthesia and intubation. The aim of the present observational study was designed to further to evaluate the diagnostic performance of lung ultrasound (LUS) in detection of postoperative atelectasis in adult patients undergoing general anesthesia. Results of LUS as the experimental method will be compared to the results of computed tomography (CT) as the reference technique for the detection of atelectasis. The investigators want to confirm former findings of the appearance of perioperative atelectases and to prove that ultrasound is a valid tool for detection of atelectases.

Eligibility criteria: Inclusion Criteria:

1. Aged 18 years and older;
2. American Society of Anesthesiologists (ASA) physical status within class I-III;
3. Scheduled for selective neurosurgical operation with general anesthesia;
4. Need of mechanical ventilation more than 2 hours;

Exclusion Criteria:

1. Patients decline to participate;
2. Pregnancy;
3. Previous thoracic procedures (thoracic drain, thoracotomy, thoracoscopy);
4. A history of pulmonary diseases within last two weeks with abnormal manifestation of lung CT (pulmonary parenchyma or/and interstitial lesions );
5. Pneumothorax or subcutaneous emphysema during peri-operation;
6. Patients with a body mass index (BMI) more than 30 kg/m2;
7. Emergency operation.

Primary outcomes:
measure: Correlation between manifestations of atelectasis in lung ultrasound and in thoracic computed tomography.
timeFrame: From 5 minutes before induction of anesthesia to 1 hour after the surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Changsha
country: China
facility: Xiangya Hospital of Central South University
state: Hunan
city: Changsha
country: China
facility: The Third Xiangya Hospital of Central South University
state: Hunan
Study officials:
References:
Clinical trial NCT02237105: The Effect of Cognitive Behavioral Therapy on the Outcome of Spinal Surgery
Official title: The Effect of Cognitive Behavioral Therapy on the Outcome of Spinal Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Back Pain
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2014-09-11
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to examine the efficacy of Cognitive Behavioral Therapy (CBT) on the outcome of spinal surgery.

The goal of this treatment is to change the coping style, thoughts, behavior and adaptive perception of the patient, and to replace them with an adaptive style.

The patients in this study will be randomly divided into two groups. One group will undergo Cognitive Behavioral Therapy (CBT) before having spinal surgery. The other group will be a control group, and will not have any psychological intervention.


Eligibility criteria: Inclusion Criteria:

* patients who intended to undergo spinal surgery

Exclusion Criteria:

* patients who does not speak Hebrew language

Primary outcomes:
measure: BSI questionnaire in spine preoperative patients .
timeFrame: 24 months
measure: OSWESTRY questionnaire in spine preoperative patients
timeFrame: 24 months
measure: SF 36 questionnaire in spine preoperative patients
timeFrame: 24 months
measure: VAS scale in spine preoperative patients
timeFrame: 24 months
Secondary outcomes:
measure: BSI questionnaire in spine postoperative patients
timeFrame: 24 months
measure: OSWESTRY questionnaire in spine postoperative patients
timeFrame: 24 months
measure: SF 36 questionnaire in postoperative patients
timeFrame: 24 months
measure: VAS scale in spine postoperative patients
timeFrame: 24 months
Other outcomes:
Locations:
city: Kfar Saba
country: Israel
facility: Meir MC
Study officials:
References:
Clinical trial NCT00309205: A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in Belgium
Official title: A Phase I/II Single-Centre Double-Blinded Randomized Study of the Safety and Tolerability of TMC120 Vaginal Microbicide Gel vs. HEC-Based Universal Placebo Gel in Healthy HIV-Negative Women.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: HIV Infections
HIV-1
Keywords: HIV seronegativity
Lead sponsor: International Partnership for Microbicides, Inc.
Sponsor class: INDUSTRY
First posted: 2006-03-31
Enrollment: 36
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Approximately 36 HIV-negative women, aged \>18 and \< 50, will be enrolled in this study. Each volunteer will have a 2:1 chance of receiving dapivirine gel versus placebo. The volunteers will receive investigational product for a total of 42 days.


Eligibility criteria: Inclusion Criteria:

* HIV-negative
* Willing to participate and sign an informed consent form
* Willing to be tested for HIV, use an experimental vaginal gel, and to be randomized to a study group that includes the possibility of being assigned to a placebo group.
* Willing to use two forms of contraception during the study
* Willing to undergo pelvic examinations with colposcopy and photographic documentation according to the protocol throughout the study.
* Have a regular menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days between menses

Exclusion Criteria:

* Currently pregnant or breast-feeding
* Clinically detectable genital abnormality on the vulva, vaginal walls or cervix
* Laboratory confirmed gonorrhea, chlamydia, trichomonas, syphilis, or vaginal candidiasis or clinically diagnosed GUD or active HSV-2 lesion
* Breakthrough bleeding or gynecologic surgery within 60 days prior to randomization
* Symptomatic bacterial vaginosis at Screening and unwilling to undergo treatment.
* Women who require treatment for tuberculosis (TB) within 21 days prior to randomization.

Primary outcomes:
measure: Local and systemic safety and tolerability.
Secondary outcomes:
Other outcomes:
Locations:
city: Antwerp
country: Belgium
facility: SGS Biopharma - Research Unit Stuivenberg
Study officials:
affiliation: IPM
name: Zeda Rosenberg, ScD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00947505: Treatment of Androgenetic Alopecia in Males
Official title: A Randomized, Double-Blind, Control Device Clinical Trial to Evaluate the Safety and Efficacy of the HairMax LaserComb 2009, 7 Beam Model: For the Treatment of Androgenetic Alopecia in Males
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Androgenetic Alopecia
Hair Loss
Male Pattern Baldness
Keywords: Androgenetic alopecia
Hair loss
Male Pattern baldness
Lead sponsor: Lexington International, LLC
Sponsor class: INDUSTRY
First posted: 2009-07-28
Enrollment: 49
Sex: MALE
Minimum age (years): 25
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 7 Beam model in promoting hair growth in males diagnosed with androgenetic alopecia when treatment is applied as directed.

Detailed description: This is randomized, double-blind, control device clinical study across 2 sites, evaluating changes in terminal hair-count in the evaluation zone having evidence of androgenetic alopecia (miniaturized hair).

The trial will involve 45 male subjects who have been diagnosed with androgenetic alopecia, who are between 25 and 60 years of age, have Fitzpatrick Skin Types I-IV, with classifications of Norwood-Hamilton IIa to V, have active hair loss within the last 12 months.

Subjects will use the device on three nonconcurring days a week as directed per device for 26 weeks treatment duration.

Initial efficacy endpoint for each subject will be assessed at visit 4 (week 16).

Safety analysis will be assessed based on the reports of adverse events during study.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of androgenetic alopecia
* Fitzpatrick Skin Types I-IV
* Norwood-Hamilton IIa to V
* Active hair loss within last 12 months

Exclusion Criteria:

* Photosensitivity to laser light
* Malignancy in the target area

Primary outcomes:
measure: Changes in Terminal Hair Count at 16 and 26 Weeks Over Baseline
timeFrame: 16 and 26 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Palm Beach
country: United States
facility: Abe Marcadis, M.D.
state: Florida
city: Austin
country: United States
facility: Michael Jarratt, MD
state: Texas
Study officials:
affiliation: DermaResearch, Inc.
name: Michael Jarratt, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Palm Beach Research Center
name: Abe Marcadis, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Leavitt M, Charles G, Heyman E, Michaels D. HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled, multicentre trial. Clin Drug Investig. 2009;29(5):283-92. doi: 10.2165/00044011-200929050-00001.
Clinical trial NCT01805505: Comparison of Embryo Transfer in Egg Donation Recipients With Transvaginal and Transabdominal Ultrasound
Official title: Comparison of Embryo Transfer in Egg Donation Recipients With Transvaginal and Transabdominal Ultrasound
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: EARLY_PHASE1
Conditions: Infertility
Keywords: Female infertility
Oocyte donation
Embryo transfer
Transvaginal ultrasonography
Transabdominal ultrasonography
Lead sponsor: IVI Madrid
Sponsor class: OTHER
First posted: 2013-03-06
Enrollment: 346
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Transabdominal ultrasound guidance is the golden standard for embryo transfers. Transvaginal ultrasound guidance was proposed recently to provide better visualization and reduce patient discomfort as embryo transfer can be performed with an empty bladder in this case. The purpose of this study is to determine whether there are any differences between transvaginal and transabdominal ultrasound-guided embryo transfer in terms of ease of use, patient satisfaction, and treatment outcome.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing oocyte donation treatment with transfer of 2 embryos on day 3

Exclusion Criteria:

* Submucous or \>3 cm intramural fibroids
* Turner syndrome
* Black recipients

Primary outcomes:
measure: Pregnancy rate
timeFrame: At performing the pregnancy test 11 days post-embryo transfer
Secondary outcomes:
measure: Clinical pregnancy rate
timeFrame: At first pregnancy ultrasound (3 weeks post-embryo transfer)
measure: Ongoing pregnancy rate
timeFrame: At 10 weeks post-embryo transfer
measure: Menstruation-like pain
timeFrame: At embryo transfer
measure: Discomfort related to vesical distension
timeFrame: At embryo transfer
measure: Overall discomfort
timeFrame: At embryo transfer
measure: Difficulty using the assigned technique faced by operators
timeFrame: At embryo transfer
measure: Catheterization time
timeFrame: At embryo transfer
measure: Conversion to the opposite technique
timeFrame: At embryo transfer
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: IVI Madrid
Study officials:
affiliation: IVI Madrid
name: Erik E Hauzman, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: IVI Madrid
name: Juan A Garcia-Velasco, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00665405: Atelectasis During Delivery - Comparing Cesarian (c) -Section and Labor
Official title: CT Study of Atelectasis After Delivery - Comparison Between Cesarian Section and Labor
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Delivery, Obstetric
Cesarean Section
Labor
Respiration Disorders
Atelectasis
Keywords: Delivery, obstetric
Atelectasis
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2008-04-23
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospital, obstetric division

Brief summary: Pregnancy promotes respiratory system's restrictive component. This study observes the generation of atelectasis during labor.

Detailed description: Pregnancy causes restriction of diaphragm movements as well as higher resistive component to the respiratory system. Spirometry studies have shown that the supine position increases risks of hypoxemia. There seems to be only casual observation regarding the generation of atelectasis during labor.

Eligibility criteria: Inclusion Criteria:

* post-anesthesia recovery

Exclusion Criteria:

* hemodynamic disorder during labor

Primary outcomes:
measure: atelectasis
timeFrame: 60-120 minutes after delivery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Sao Paulo Medical School - FMUSP
name: Joaquim E Vieira, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02944305: A Predictive Model for Difficult Intubation
Official title: A New Prognostic Model Developed by Using Multi-predictive Tests for Prediction of Difficult Intubation in Adult Anesthetic Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Difficult Intubation
Lead sponsor: Khon Kaen University
Sponsor class: OTHER
First posted: 2016-10-25
Enrollment: 7500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients undergoing general anesthesia with endotracheal intubation

Brief summary: Failure in airway management is one of the most common anesthesia-related morbidity and mortality. Each individual airway assessment has limitation to predict difficult intubation.

Detailed description: Objective: To develop a scoring model from multiple airway assessment to predict difficult intubation.

Methods: This will be a retrospective analytic study. All airway assessment data from medical records of patients aged more than 18 years old underwent general anesthesia in Srinagarind hospital from January 2012 to December 2014 will be used to develop a new scoring prediction model.

Eligibility criteria: Inclusion Criteria:

* Adult patients undergoing general anesthesia with endotracheal intubation

Exclusion Criteria:

* Incomplete airway assessment in medical record

Primary outcomes:
measure: Difficult intubation
timeFrame: 5 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Khon Kaen
country: Thailand
facility: Srinagarind Hospital, Faculty of Medicine, Khon Kaen University
Study officials:
affiliation: Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
name: Sirirat Tribuddharat, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Adnet F, Borron SW, Racine SX, Clemessy JL, Fournier JL, Plaisance P, Lapandry C. The intubation difficulty scale (IDS): proposal and evaluation of a new score characterizing the complexity of endotracheal intubation. Anesthesiology. 1997 Dec;87(6):1290-7. doi: 10.1097/00000542-199712000-00005.
citation: Adnet F, Racine SX, Borron SW, Clemessy JL, Fournier JL, Lapostolle F, Cupa M. A survey of tracheal intubation difficulty in the operating room: a prospective observational study. Acta Anaesthesiol Scand. 2001 Mar;45(3):327-32. doi: 10.1034/j.1399-6576.2001.045003327.x.
citation: Aktas S, Atalay YO, Tugrul M. Predictive value of bedside tests for difficult intubations. Eur Rev Med Pharmacol Sci. 2015;19(9):1595-9.
citation: Iohom G, Ronayne M, Cunningham AJ. Prediction of difficult tracheal intubation. Eur J Anaesthesiol. 2003 Jan;20(1):31-6. doi: 10.1017/s0265021503000061.
citation: Merah NA, Foulkes-Crabbe DJ, Kushimo OT, Ajayi PA. Prediction of difficult laryngoscopy in a population of Nigerian obstetric patients. West Afr J Med. 2004 Jan-Mar;23(1):38-41. doi: 10.4314/wajm.v23i1.28079.
Clinical trial NCT02885805: Sun Protection Factor (SPF) Efficacy Assay
Official title: Sun Protection Factor (SPF) Efficacy Assay
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sunscreen Agents
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-09-01
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Evaluation of the effectiveness of a sunscreen product by determining its Sun Protection Factor (SPF) on the skin of human subjects.


Eligibility criteria: Inclusion Criteria:

* Fitzpatrick Skin Type I, II and/or 111 for UVB testing; Fitzpatrick Skin Type II, 111 and/or IV for UVA testing.
* Sex: Male or female.
* Age: 18-70 years.
* Good health as determined from the HRL SHF.
* Signed and dated lnformed Consent Form.
* Signed and dated HIPAA Form.
* An unambiguous MED or MPPD

Primary outcomes:
measure: Sun Protection Factor (SPF) efficacy on the skin of human subjects before a total of 2 hours of water Immersion
timeFrame: up to 24 hours post-exposure
measure: Sun Protection Factor (SPF) efficacy on the skin of human subjects after a total of 2 hours of water Immersion
timeFrame: up to 24 hours post-exposure
Secondary outcomes:
Other outcomes:
Locations:
city: Union
country: United States
state: New Jersey
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT05312905: Mirror Therapy in Stroke
Official title: Home-based Mirror Therapy and Cognitive Therapeutic Exercises After Stroke
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Cognitive Therapy
Telerehabilitation
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2022-04-06
Enrollment: 30
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Little is known about mirror therapy and cognitive exercises applied together in patients with stroke by means of telerehabilitation. The aim of this study is to investigate the effects of home-based mirror therapy combined with cognitive exercises on upper extremity functions and cognition in adults with stroke and to compare these effects with mirror therapy alone.


Eligibility criteria: Inclusion Criteria:

Age 40 years old and over having had a stroke having unilateral involvement having sufficient communication skills to answer oral and written questions and following instructions 20\< points in MMSE

Exclusion Criteria:

a stroke history under the age of 40 not having a verbal or written communication level that cannot fulfill the study conditions

Primary outcomes:
measure: Mini-Mental State Examination
timeFrame: changes after 8 weeks
measure: Fugl-Meyer Upper Extremity Motor Assessment
timeFrame: changes after 8 weeks
Secondary outcomes:
measure: Stroke-Specific Quality of Life Scale
timeFrame: changes after 8 weeks
measure: Beck Depression Scale
timeFrame: changes after 8 weeks
measure: Barthel Activity of Daily Living Scale
timeFrame: changes after 8 weeks
measure: Modified Ashworth Scale
timeFrame: changes after 8 weeks
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Medipol University
Study officials:
References:
Clinical trial NCT04802005: Effects of a Short-term Aerobic Interval Exercise Program on Cardiac Fat and Function in Women With Obesity: A Pilot Study
Official title: Effects of a Short-term Aerobic Interval Exercise Program on Cardiac Fat and Function in Women With Obesity: A Pilot Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Obesity
Keywords: Cardiac fat
Cardiac function
Aerobic interval training
Cardiac Magnetic Resonance
Vascular health
Lead sponsor: Southern Illinois University Edwardsville
Sponsor class: OTHER
First posted: 2021-03-17
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The overall goal of this project is to the study the effects of an aerobic interval training program on cardiac fat, and its relationship to cardiac function using cardiac Magnetic Resonance Imaging.


Eligibility criteria: Inclusion Criteria:

* females, age 18-40 years old, body mass index (BMI) ≥ 30 kg/m2 and \< 39.9 kg/m2, without known metabolic and/or cardiovascular disease

Exclusion Criteria:

* known CV, metabolic or pulmonary diseases or conditions, muscular-skeletal injuries (i.e. spine, knees, hips or shoulders, taking medications that affect endocrine or cardiovascular function, hypertension, being engaged in moderate intensity exercise more than two times per week or moderate-high intensity training of any type and frequency, being pregnant, cigarette smoking, having non-removable pieces or devices incompatible with DXA and CMR assessment

Primary outcomes:
measure: Changes in Cardiac Adipose Tissue (CAT)
timeFrame: 2 assessment points: at baseline and week 5
measure: Changes in Cardiac Function
timeFrame: 2 assessment points: at baseline and week 5
Secondary outcomes:
measure: Changes in Body Composition
timeFrame: 2 assessment points: at baseline and week 5
measure: Changes in Cardiorespiratory Function
timeFrame: 2 assessment points: at baseline and week 5
measure: Changes in Muscular Strength
timeFrame: 2 assessment points: at baseline and week 5
measure: Changes in Blood Pressure
timeFrame: 2 assessment points: at baseline and week 5
Other outcomes:
Locations:
city: Edwardsville
country: United States
facility: Southern Illinois University Edwardsville
state: Illinois
Study officials:
affiliation: Southern Illinois University of Edwardsville
name: Maria Fernandez Del Valle, PhD
role: PRINCIPAL_INVESTIGATOR
References: